Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

FLT3-ITD Interacts with and Phosphorylates IL-3β, and JAK1/2 Dependent IL-3β Activation Bypasses FLT3-ITD in FLT3 Kinase Independent Inhibitor Resistance in Vitro: Evidence for the Significance of IL-3β for FLT3-ITD Dependent Oncogeneic Signaling in AML.

Christoph Rummelt, Sivahari P. Gorantla, Michael Sigl, Jana Saenger, Katharina Götze, Christian Peschel, MD, Justus Duyster, Nikolas von Bubnoff

Blood (2012) 120 (21): 2423.

https://doi.org/10.1182/blood.V120.21.2423.2423

Published: 2012

Journal Articles

Different FLT3 Inhibitors Display Limited, Non-Overlapping Profiles of Specific FLT3-ITD Resistance Mutations in a Cell-Based Screen.

Nikolas von Bubnoff, MD, Jana Saenger, Christian Peschel, MD, Justus Duyster, MD

Blood (2007) 110 (11): 870.

https://doi.org/10.1182/blood.V110.11.870.870

Published: 2007

Journal Articles

Generation of Specific Resistance Profiles in FLT3-ITD and FIP1L1-PDGFRalpha towards Specifically Acting Tyrosine Kinase Inhibitors.

Nikolas von Bubnoff, MD, Silvia Thoene, Sivahari P. Gorantla, Jana Saenger, Christian Peschel, MD, Justus Duyster, MD

Blood (2006) 108 (11): 1376.

https://doi.org/10.1182/blood.V108.11.1376.1376

Published: 2006

Journal Articles

Bcr-Abl Resistance Screening Predicts a Limited Spectrum of Point Mutations To Be Associated with Clinical Resistance to the Abl Kinase Inhibitor AMN107.

Nikolas von Bubnoff, Jana Saenger, Paul W. Manley, Juergen Mestan, Christian Peschel, Justus Duyster

Blood (2005) 106 (11): 1983.

https://doi.org/10.1182/blood.V106.11.1983.1983

Published: 2005

Journal Articles

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Nikolas von Bubnoff, M.D., Darren R. Veach, Ph.D., Heiko van der Kuip, Ph.D., Walter E. Aulitzky, M.D., Jana Saenger, Petra Seipel, William G. Bornmann, Ph.D., Christian Peschel, M.D., Bayard Clarkson, M.D., Justus Duyster, M.D.

Blood (2004) 104 (11): 558.

https://doi.org/10.1182/blood.V104.11.558.558

Published: 2004

NARROW

FLT3-ITD Interacts with and Phosphorylates IL-3β, and JAK1/2 Dependent IL-3β Activation Bypasses FLT3-ITD in FLT3 Kinase Independent Inhibitor Resistance in Vitro: Evidence for the Significance of IL-3β for FLT3-ITD Dependent Oncogeneic Signaling in AML.

Different FLT3 Inhibitors Display Limited, Non-Overlapping Profiles of Specific FLT3-ITD Resistance Mutations in a Cell-Based Screen.

Generation of Specific Resistance Profiles in FLT3-ITD and FIP1L1-PDGFRalpha towards Specifically Acting Tyrosine Kinase Inhibitors.

Bcr-Abl Resistance Screening Predicts a Limited Spectrum of Point Mutations To Be Associated with Clinical Resistance to the Abl Kinase Inhibitor AMN107.

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

FLT3-ITD Interacts with and Phosphorylates IL-3β, and JAK1/2 Dependent IL-3β Activation Bypasses FLT3-ITD in FLT3 Kinase Independent Inhibitor Resistance in Vitro: Evidence for the Significance of IL-3β for FLT3-ITD Dependent Oncogeneic Signaling in AML.

Different FLT3 Inhibitors Display Limited, Non-Overlapping Profiles of Specific FLT3-ITD Resistance Mutations in a Cell-Based Screen.

Generation of Specific Resistance Profiles in FLT3-ITD and FIP1L1-PDGFRalpha towards Specifically Acting Tyrosine Kinase Inhibitors.

Bcr-Abl Resistance Screening Predicts a Limited Spectrum of Point Mutations To Be Associated with Clinical Resistance to the Abl Kinase Inhibitor AMN107.

A Cell-Based Screening Method for Resistance of Bcr-Abl Positive Leukemia Identifies the Mutation Pattern for an Alternative Abl Kinase Inhibitor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only